Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

(2016) Marc S. Sabatine et al.   AMERICAN HEART JOURNAL

Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia

(2016) Ioanna Gouni-Berthold et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

(2016) Shravanthi R. Gandra et al.   CLINICAL CARDIOLOGY

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Transatlantic Editorial: a comparison between European and North American guidelines on myocardial revascularization

(2016) Philippe Kolh et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

(2016) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality

(2016) Rishi K. Wadhera et al.   Journal of Clinical Lipidology

A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia

(2015) Henry J. Henk et al.   ADVANCES IN THERAPY

Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance

(2015) Dirk J. Blom et al.   CIRCULATION RESEARCH

Burden of First and Recurrent Cardiovascular Events Among Patients With Hyperlipidemia

(2015) Rajeshwari S. Punekar et al.   CLINICAL CARDIOLOGY

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

(2015) Tomas Jernberg et al.   EUROPEAN HEART JOURNAL

High-Risk Atherosclerotic Cardiovascular Disease in a Real-World Employed Japanese Population: Prevalence, Cardiovascular Event Rates, and Costs

(2015) Keith L Davis et al.   Journal of Atherosclerosis and Thrombosis

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

(2015)   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Economic Burden Associated With Cardiovascular Events Among High-Risk Patients With Hyperlipidemia

(2015) K.M. Fox et al.   VALUE IN HEALTH

ACC/AHA Statement on Cost/Value Methodology in Clinical Practice Guidelines and Performance Measures

(2014) Jeffrey L. Anderson et al.   CIRCULATION

Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk

(2014) Atsushi Hirayama et al.   CIRCULATION JOURNAL

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

(2014) Jennifer G. Robinson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-PCSK9 Monotherapy for Hypercholesterolemia

(2014) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

1-Year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab

(2013) Bryony M. Mearns   Nature Reviews Cardiology

Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke)

(2012) et al.   EUROPEAN HEART JOURNAL

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

(2012) David Sullivan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Health Care for Older Persons in England and the United States: A Contrast of Systems and Values

(2011) Michael Gusmano et al.   JOURNAL OF HEALTH POLITICS POLICY AND LAW

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure

(2009) Michael J. Lipinski et al.   AMERICAN JOURNAL OF CARDIOLOGY

Harmonizing the Metabolic Syndrome

(2009) K.G.M.M. Alberti et al.   CIRCULATION

ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System

(2008) Linda S. Tyler et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY